Twist Bioscience
TWST
103.32
-8.30
-7.44%
Twist Bioscience
US · TWST
#1258 by market cap
Listed 2018
103.32
-8.30
-7.44%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:52
Recent news
-
Rating change
Piper Sandler Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $115\u5e02\u573a\u8d44\u8baf · 2026/8/5
-
Rating change
Guggenheim Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $212\u5e02\u573a\u8d44\u8baf · 2026/10/1
-
Rating change
TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $190\u5e02\u573a\u8d44\u8baf · 2026/10/13
-
Rating change
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $215\u5e02\u573a\u8d44\u8baf · 2026/10/7
-
Rating change
William Blair Maintains Twist Bioscience(TWST.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/8/4
-
Rating change
Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $110\u5e02\u573a\u8d44\u8baf · 2026/7/17
-
Rating change
TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $115\u5e02\u573a\u8d44\u8baf · 2026/8/4
-
Rating change
Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $110\u5e02\u573a\u8d44\u8baf · 2026/7/16
-
Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $175\u5e02\u573a\u8d44\u8baf · 2026/11/16
-
Rating change
CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $120\u5e02\u573a\u8d44\u8baf · 2026/8/4
-
Rating change
Baird Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $115\u5e02\u573a\u8d44\u8baf · 2026/8/4
-
A Quick Look at Today's Ratings for Twist Bioscience(TWST.US), With a Forecast Between $135 to $175\u5e02\u573a\u8d44\u8baf · 2026/11/14
-
Rating change
Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $160\u5e02\u573a\u8d44\u8baf · 2026/9/17
-
CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Cuts Target Price to $150\u5e02\u573a\u8d44\u8baf · 2026/11/13
-
Rating change
BWS Financial Initiates Twist Bioscience(TWST.US) With Sell Rating, Announces Target Price $45\u5e02\u573a\u8d44\u8baf · 2026/9/10
-
Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q4 Revenue $126.6M, Vs. FactSet Est of $123.5MMT Newswires · 2026/11/12
-
Rating change
Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $190\u5e02\u573a\u8d44\u8baf · 2026/9/29
-
Rating change
BWS Financial Maintains Twist Bioscience(TWST.US) With Sell Rating, Maintains Target Price $45\u5e02\u573a\u8d44\u8baf · 2026/9/18
-
Rating change
CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $205\u5e02\u573a\u8d44\u8baf · 2026/10/12
-
Guggenheim Maintains Twist Bioscience(TWST.US) With Buy Rating, Cuts Target Price to $150\u5e02\u573a\u8d44\u8baf · 2026/11/13
-
Rating change
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $95\u5e02\u573a\u8d44\u8baf · 2026/6/24
-
Rating change
Evercore Downgrades Twist Bioscience(TWST.US) to Hold Rating, Raises Target Price to $102\u5e02\u573a\u8d44\u8baf · 2026/7/6
-
Trade.xyz announces the listing of synthetic DNA company TWST.Latest · 2026/10/8
-
Rating change
Guggenheim Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $107\u5e02\u573a\u8d44\u8baf · 2026/6/29
-
Rating change
CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $120\u5e02\u573a\u8d44\u8baf · 2026/7/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:52:04 · For reference only, not investment advice and not tailored to your situation.
Twist Bioscience discussion 0 comments